Because obesity-related metabolic dysfunction could modify the response to asthma treatments, the GATA-3 study will systematically monitor metabolic parameters, including lipid profile (triglycerides, total cholesterol, high-density lipoprotein, and low-density lipoprotein), A1c, fasting insulin, and fasting glucose at baseline and throughout treatment. The gene discussed is GATA3; the disease is obesity disorder.